Key additions deepen drug development expertise and position the Company to advance pipeline VANCOUVER, British Columbia, Feb. 10, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds” or the “Company”), a biosciences company focused on creating the next generation of psychedelic and related therapies for the treatment of mental health and central nervous system disorders…


Previous articleNew Toad Venom Compound Synthesized for Clinical Use: 5-MeO-DMT Succinate
Next articleFeb 10: $SPOR +40.91%, $PSYC +35.42%, $MCUR +23.33%